Apellis Pharmaceuticals I... (APLS)
Apellis Pharmaceuticals Statistics
Share Statistics
Apellis Pharmaceuticals has 125.52M shares outstanding. The number of shares has increased by 3.16% in one year.
| Shares Outstanding | 125.52M |
| Shares Change (YoY) | 3.16% |
| Shares Change (QoQ) | 2.16% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 104.48M |
| Failed to Deliver (FTD) Shares | 9.17K |
| FTD / Avg. Volume | 0.49% |
Short Selling Information
The latest short interest is 18.04M, so 14.5% of the outstanding shares have been sold short.
| Short Interest | 18.04M |
| Short % of Shares Out | 14.5% |
| Short % of Float | 17.83% |
| Short Ratio (days to cover) | 7.7 |
Valuation Ratios
The PE ratio is -19.98 and the forward PE ratio is -28.78. Apellis Pharmaceuticals's PEG ratio is 0.31.
| PE Ratio | -19.98 |
| Forward PE | -28.78 |
| PS Ratio | 5.57 |
| Forward PS | 1.8 |
| PB Ratio | 17.3 |
| P/FCF Ratio | -44.79 |
| PEG Ratio | 0.31 |
Enterprise Valuation
Apellis Pharmaceuticals Inc. has an Enterprise Value (EV) of 6.86B.
| EV / Earnings | -34.68 |
| EV / Sales | 9.67 |
| EV / EBITDA | -29.03 |
| EV / EBIT | -29.03 |
| EV / FCF | -77.75 |
Financial Position
The company has a current ratio of 4.25, with a Debt / Equity ratio of 2.06.
| Current Ratio | 4.25 |
| Quick Ratio | 3.81 |
| Debt / Equity | 2.06 |
| Total Debt / Capitalization | 67.27 |
| Cash Flow / Debt | -0.19 |
| Interest Coverage | -5.85 |
Financial Efficiency
Return on equity (ROE) is -0.87% and return on capital (ROIC) is -34.05%.
| Return on Equity (ROE) | -0.87% |
| Return on Assets (ROA) | -0.22% |
| Return on Capital (ROIC) | -34.05% |
| Revenue Per Employee | $1,007,026.95 |
| Profits Per Employee | $-280,678.01 |
| Employee Count | 705 |
| Asset Turnover | 0.8 |
| Inventory Turnover | 1.45 |
Taxes
| Income Tax | 1.16M |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -58.69% in the last 52 weeks. The beta is 0.92, so Apellis Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.92 |
| 52-Week Price Change | -58.69% |
| 50-Day Moving Average | 27.08 |
| 200-Day Moving Average | 32.29 |
| Relative Strength Index (RSI) | 40.15 |
| Average Volume (20 Days) | 1.86M |
Income Statement
In the last 12 months, Apellis Pharmaceuticals had revenue of 709.95M and earned -197.88M in profits. Earnings per share was -1.6.
| Revenue | 709.95M |
| Gross Profit | 592.23M |
| Operating Income | -236.39M |
| Net Income | -197.88M |
| EBITDA | -236.39M |
| EBIT | -236.39M |
| Earnings Per Share (EPS) | -1.6 |
Balance Sheet
The company has 411.29M in cash and 469.78M in debt, giving a net cash position of -58.49M.
| Cash & Cash Equivalents | 411.29M |
| Total Debt | 469.78M |
| Net Cash | -58.49M |
| Retained Earnings | -3.04B |
| Total Assets | 885.05M |
| Working Capital | 603.45M |
Cash Flow
In the last 12 months, operating cash flow was -87.87M and capital expenditures -403K, giving a free cash flow of -88.27M.
| Operating Cash Flow | -87.87M |
| Capital Expenditures | -403K |
| Free Cash Flow | -88.27M |
| FCF Per Share | -0.71 |
Margins
Gross margin is 83.42%, with operating and profit margins of -33.3% and -27.87%.
| Gross Margin | 83.42% |
| Operating Margin | -33.3% |
| Pretax Margin | -27.71% |
| Profit Margin | -27.87% |
| EBITDA Margin | -33.3% |
| EBIT Margin | -33.3% |
| FCF Margin | -12.43% |
Dividends & Yields
APLS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -6.59% |
| FCF Yield | -2.9% |
Analyst Forecast
The average price target for APLS is $40, which is 64.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $40 |
| Price Target Difference | 64.7% |
| Analyst Consensus | Buy |
| Analyst Count | 18 |
Scores
| Altman Z-Score | -0.9 |
| Piotroski F-Score | 3 |